Program
rilzabrutinib
Also written as “Rilzabrutinib”, “rilzabrutinib SAR444671” and “Rilzabrutinib dose 1”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Anemia, Hemolytic, Autoimmune · Immunoglobulin G4-Related Disease · Pemphigus · Common Variable Immunodeficiency, led by Sanofi.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 2311 open or running | phase 3since Nov 29, 2018 | Feb 24, 2016 | Nov 25, 2026phase 3 · NCT07216079 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Feb 24, 2016.
- Feb 3, 2021Phase 1 study in Healthy VolunteersNCT04748926 · 24 enrolled · Australia
- Aug 5, 20212 phase 2 studiesNCT05002777, NCT05018806
- Oct 17, 20212 phase 2 studiesNCT05104892, NCT05107115
- Mar 18, 2024Phase 1 study in Autoimmune DiseasesNCT06342700 · 28 enrolled · United States
- May 30, 20242 phase 1 studiesNCT06444204, NCT06444191
- Jul 8, 2024Phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702 · 84 planned · United States, Argentina, Australia and more
- May 8, 20252 phase 3 studiesNCT06975865, NCT07007962
- May 14, 2025Phase 2 study in Graves DiseaseNCT06984627 · 30 planned · Argentina, Canada, Chile and more
- Jul 17, 2025Phase 3 study in Anemia, Hemolytic, AutoimmuneNCT07086976 · 90 planned · United States, Argentina, Austria and more
- Sep 17, 2025Phase 3 study in Immunoglobulin G4-Related DiseaseNCT07190196 · 124 planned · United States, Argentina, Belgium and more
- Oct 9, 2025Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07216079 · 3 enrolled · Japan
- Sep 21, 20262 phase 1 studiesNCT07855250, NCT07853131
- Oct 1, 2026Primary completion moved from 2026-08-25 to 2027-02-11Date moved laterphase 2 · +6 months · NCT06984627
- Oct 28, 2026Phase 3 study in Common Variable ImmunodeficiencyNCT07923305 · 96 planned
Ahead
- Nov 3, 2026Primary completion: phase 1 study in Healthy VolunteerNCT07855250
- Nov 25, 2026Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07216079
- Dec 23, 2026Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702
- Feb 11, 2027Primary completion: phase 2 study in Graves DiseaseNCT06984627
TargetBeta
“An orally bioavailable reversible covalent inhibitor of Bruton's tyrosine kinase (BTK), ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07923305Common Variable Immunodeficiency | 3 | Not yet recruiting | May 10, 2035 | 96 |
| NCT07853131Renal Insufficiency · United States | 1 | Recruiting | Apr 21, 2027 | 16 |
| NCT07855250Healthy Volunteer · Canada | 1 | Active, not recruiting | Nov 3, 2026 | 14 |
| NCT07216079Purpura, Thrombocytopenic, Idiopathic · Japan | 3 | Active, not recruiting | Nov 25, 2026 | 3 |
| NCT07190196Immunoglobulin G4-Related Disease · United States, Argentina, Belgium and more | 3 | Recruiting | Jun 28, 2028 | 124 |
| NCT07086976Anemia, Hemolytic, Autoimmune · United States, Argentina, Austria and more | 3 | Recruiting | May 31, 2028 | 90 |
| NCT07007962Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Czechia and more | 3 | Recruiting | Nov 5, 2027 | 60 |
| NCT06984627Graves Disease · Argentina, Canada, Chile and more | 2 | Recruiting | Feb 11, 2027 | 30 |
| NCT06975865Anemia, Sickle Cell · United States, Belgium, Brazil and more | 3 | Recruiting | Jul 23, 2027 | 192 |
| NCT06500702Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more | 2 | Recruiting | Dec 23, 2026 | 84 |
| NCT06444204Liver Diseases · United States | 1 | Completed | Mar 23, 2021 | 29 |
| NCT06444191Healthy Volunteers · United States | 1 | Completed | Apr 12, 2021 | 23 |
| NCT06342700Autoimmune Diseases · United States | 1 | Completed | Apr 23, 2024 | 28 |
| NCT05107115Chronic Urticaria · Argentina, Canada, Chile and more | 2 | Completed | Jul 19, 2023 | 160 |
| NCT05104892Asthma · Argentina, Bulgaria, Canada and more | 2 | Completed | Feb 6, 2024 | 196 |
| NCT05018806Dermatitis, Atopic · United States, Canada, Chile and more | 2 | Completed | Jun 23, 2023 | 124 |
| NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA) · United States, Austria, China and more | 2 | Active, not recruiting | May 23, 2024 | 22 |
| NCT04748926Healthy Volunteers · Australia | 1 | Completed | May 21, 2021 | 24 |
| NCT04562766Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Completed | Jan 15, 2025 | 232 |
| NCT04520451Immunoglobulin G4-Related Disease · United States, Canada, France and more | 2 | Completed | Oct 15, 2024 | 27 |
| NCT03762265Pemphigus · United States, Argentina, Australia and more | 3 | Terminated | Jul 30, 2021 | 131 |
| NCT03395210Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Bulgaria and more | 2 | Completed | Jan 31, 2023 | 86 |
| NCT02704429Pemphigus · Australia, Croatia, France and more | 2 | Completed | Dec 18, 2019 | 42 |
How it is read
Names in the registry
- “Rilzabrutinib”, 10 entries
- “rilzabrutinib”, 9 entries
- “rilzabrutinib SAR444671”, 3 entries
- “Rilzabrutinib dose 1”, 1 entry
- “Rilzabrutinib dose 2”, 1 entry
Codes read as this program: SAR444671.
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 4 studies
- Anemia, Hemolytic, Autoimmune, 2 studies
- Immunoglobulin G4-Related Disease, 2 studies
- Pemphigus, 2 studies
- Common Variable Immunodeficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.